The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nordion Launches a New and Improved TheraSphere® Website to Meet the Needs of Liver Cancer Physician
OTTAWA, Ontario--(BUSINESS WIRE)-- Nordion Inc. (TSX: NDN) (NYS: NDZ) , a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced today that it has ...
OTTAWA, Ontario--(BUSINESS WIRE)-- Nordion Inc. (TSX: NDN) (NYS: NDZ) , a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced that for the ...
The approval was based on data from the LEGACY study, a single-arm, retrospective trial that evaluated treatment with TheraSphere Y90 glass microspheres in 162 patients with unresectable ...
MILWAUKEE (WITI) -- A local man who built a multimedia empire from the ground up is now broadcasting the benefits of a relatively new cancer treatment. For more than 50 years, Vic Eliason has been a ...
Boston Scientific Corporation BSX recently announced favorable study outcome of the TARGET study of its TheraSphere Y-90 Glass Microspheres (TheraSphere) therapy during a late-breaking clinical trial ...
Nordion announced an additional randomized, multi-centre Phase III clinical trial for TheraSphere , Nordion's yttrium-90, or Y-90, glass microsphere treatment for liver cancer. The YES-P trial will be ...
(RTTNews) - Boston Scientific Corp. (BSX) said that late-breaking data demonstrated improved progression-free survival in patients with metastatic colorectal cancer after treatment with boston ...
Boston Scientific announced an analysis of 989 patients with hepatocellular carcinoma (HCC) from the PROACTIF prospective ...
NICE has issued guidance recommending the use of TheraSphere Y-90 Glass Microspheres, from Boston Scientific, as a treatment for patients with HCC. The National Institute for Health and Care ...
Nordion announced results from its Phase 2 multisite clinical trial of TheraSphere for the treatment of metastatic liver cancer. The trial evaluated safety and tumor response in 151 patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results